Thanich Sangsuwannukul

5PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 21, 2026
Immunodominant Antiviral T Cell Responses Outcompete Antitumor T Cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy.

|Aug 26, 2026
Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome.

|Jun 05, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

|Apr 01, 2025
Immunodominant antiviral T cell responses outcompete immuno-subdominant antitumor responses to reduce the efficacy of oncolytic viroimmunotherapy.

Richard Vile, Benjamin Kendall, Olivia Liseth

|Jun 27, 2024
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.

Mason J Webb, Thanich Sangsuwannukul, Jacob van Vloten

Pageof 1

Frequent Collaborators

5 joint publications

Richard Vile

4 joint publications

Alan Melcher

3 joint publications

Benjamin L Kendall

3 joint publications

Jill Thompson